What smart money is saying about Johnson & Johnson
3 funds in our archive have pitched Johnson & Johnson, most recently Mar Vista U.S. Quality in March 2026.
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Get an email when a fund buys, sells or pitches it
Position history
Between Q2 2025 and Q3 2026, 18 fund letters reported a position in Johnson & Johnson, with 2 buys (opened or added) and 1 sell (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 4 | 1 | 0 | 0 |
| Q2 2026 | 3 | 0 | 0 | 0 |
| Q1 2026 | 2 | 0 | 0 | 3 |
| Q4 2025 | 5 | 1 | 0 | 0 |
| Q3 2025 | 2 | 0 | 0 | 0 |
| Q2 2025 | 2 | 0 | 1 | 0 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 18 positions · 3 moves
- September 2026
“We added to positions in Johnson & Johnson (J&J), Merck & Co., Inc., and Vertex Pharmaceuticals Incorporated.”
Johnson & Johnson - September 2026
Listed in Harding Loevner Global Developed Markets Equity’s reported holdings.
Johnson & Johnson - September 2026
Listed in Buffalo funds Flexible Allocation Fund’s reported holdings.
Johnson & Johnson - HoldsSomma Investimentos Fund FamilySeptember 2026
“The Open Vista Medical Sciences fund presented, in September, a return decline of 0.4%, equivalent to a decline of 0.1% in dollars. The global healthcare sector registered a decline of 1.8% in dollars in the month, therefore the fund presented performance considerably superior to the sector's performance. In September 2026, the global healthcare sector presented a divergence between the improvement in fundamentals and the lag in capital allocation. After two years of valuation compression of the sector's leading companies, the fundamental inflection point of the pharmaceutical and life sciences segments was confirmed by multiple positive indicators throughout September, but the global allocation of investors in the sector remained below expectations, with the flow of resources extremely concentrated in AI infrastructure, which ended up masking the earnings dynamics that the healthcare sector has been accumulating. From the point of view of sector dynamics, the most relevant change in September came from the dissipation of regulatory uncertainty and the acceleration of the innovation cycle. The signals emitted at the 24th Global Healthcare Conference of Morgan Stanley bank indicated that policymakers in the United States began to prioritize "sector stability" and greater clarity on tariffs and the drug pricing framework significantly reduced risk. In parallel, an outlook report published by Credit Lyonnais Securities, in early September, pointed out that the global pharmaceutical supply chain is entering a decade-long restructuring period, with more than US$ 500 billion in branded drug sales facing patent expiration between 2026 and 2032 — the so-called "patent cliff" —, which will force large pharmaceutical companies to intensify investments in R&D and mergers and acquisitions activities, especially benefiting life sciences companies and contract development and manufacturing platforms with scale and global presence. Among the activities of companies in the sector, the approval by Eli Lilly of the combination drug Inluriyo with Verzenio, to treat certain cases of advanced or metastatic breast cancer, stands out. In the clinical study, the combination provided a median progression-free survival, that is, the period in which the disease did not worsen, of 11.1 months, versus 5.5 months with Inluriyo alone. Novartis received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for Cosentyx, an anti-inflammatory drug intended for the treatment of polymyalgia rheumatica. The opinion is not yet equivalent to final approval by the European Union. Roche reported that the treatment evaluated in the CELESTIMO study statistically significantly improved progression-free survival in patients with follicular lymphoma and also announced the European approval of Susvimo, a treatment system for a form of age-related macular degeneration that causes vision loss. AstraZeneca also reported advances with Etcamah, intended for certain cases of advanced breast cancer, and with tozorakimab, aimed at respiratory diseases such as chronic obstructive pulmonary disease. Novo Nordisk presented results from CagriSema, an experimental combination of two drugs for obesity and diabetes, which had not yet received regulatory approval. Together, these events show innovation in oncology, obesity, diabetes, ophthalmology and respiratory diseases. The clinical indicators were disclosed by the companies themselves and may be subject to methodological limitations and have not yet been converted into estimates of revenue, profit or stock returns. The fund's main positions include pharmaceutical and biotechnology companies such as Eli Lilly, Johnson & Johnson, Abbvie and Merck, which together represent 27.1% of the fund's investments, in addition to health insurance companies, with emphasis on UnitedHealth. The ten largest positions represent 50.8% of the fund's net assets.”
Johnson & Johnson - June 2026
Listed in Harding Loevner Global Equity’s reported holdings.
Johnson & Johnson - June 2026
Listed in Guinness Global Equity Income Fund’s reported holdings.
Johnson & Johnson - June 2026
Listed in Baron Health Care Fund’s reported holdings.
Johnson & Johnson - March 2026
“Johnson & Johnson (JNJ) appreciated 18.74% during the first quarter driven by strong Innovative Medicine growth, improved outlook for the medical device segment, and management’s comment that there is a “line of sight” to double-digit revenue growth by the end of the decade.”
Johnson & Johnson - March 2026
“Top Q1 portfolio contributors were Johnson & Johnson (JNJ), Linde (LIN) and Analog Devices (ADI).”
Johnson & Johnson - December 2025
“Health care names dominated top relative contributors as well: Danaher benefited from a cyclical turnaround in its bioprocessing segment, investors are increasingly convinced that cancer and inflammation medicine growth and recent deals will allow Johnson & Johnson to grow through the loss of Stelara exclusivity.”
Johnson & Johnson - December 2025
“Johnson & Johnson (+12.3%) had a strong third-quarter earnings report that led the company to raise its full-year sales guidance.”
Johnson & Johnson - New positionClearbridge Global Growth StrategyDecember 2025
“In addition to the transactions mentioned above, we added positions in Walmart and PT Unilever in consumer staples, MTU Aero Engines, Ferguson, Eaton and Sandvik in industrials, Ulta Beauty in consumer discretionary, Johnson & Johnson and CG Oncology in health care, Nu Holdings in financials and Amphenol in IT.”
Johnson & Johnson - December 2025
“In the US, Johnson & Johnson had a strong 3Q earnings report that led the company to raise its full-year sales guidance.”
Johnson & Johnson - HoldsMar Vista US QualityDecember 2025
“Johnson & Johnson (JNJ) stock demonstrated strong performance in Q4, driven by robust financial results, upward guidance revisions, and accelerating growth for the pharmaceutical and medical technology segments.”
Johnson & Johnson - September 2025
“A better outlook from Johnson & Johnson, where Tremfya could be a next-gen immunology leader, and for CVS Health, on track toward recovery in its Medicare Advantage insurance book, more than offset weakness in GLP-1 maker Novo Nordisk, which we exited.”
Johnson & Johnson - September 2025
“In Health Care, Johnson & Johnson delivered a robust second quarter earnings report that exceeded consensus expectations and included a notable upward revision to full-year guidance, supported by a strong performance in its medical devices segment, driven by continued post-pandemic recovery in elective procedures and strong growth in interventional solutions and orthopedics.”
Johnson & Johnson - ExitedTitan Wealth Global Blue ChipJune 2025
“Johnson & Johnson (–0.34%): Sector rotation and political risk pushed us to exit.”
Johnson & Johnson - June 2025
Listed in Madison Dividend Income Fund’s reported holdings.
Johnson & Johnson
Also mentioned · 3
These funds discuss Johnson & Johnson as a competitor, benchmark or comparable, without disclosing a position in it.
- October 2026
“Key companies in this network include:”
Johnson & Johnson - June 2026
“Shares of Micron, the largest producer of storage chips, skyrocketed 240%, adding over $900 billion of market cap — more than the entire market capitalization of Exxon Mobil, Johnson & Johnson or JPMorgan Chase.”
Johnson & Johnson - June 2025
“increased competition from larger players, such as Johnson & Johnson and Alcon, which have aggressively bundled and discounted similar, but what we think are inferior, products;”
Johnson & Johnson
Fund coverage · 3 theses
- Mar Vista U.S. QualityMarch 2026
Johnson & Johnson is a diversified healthcare company with accelerating pharma and MedTech growth, pipeline durability, and emerging robotic surgery optionality supporting defensive long-term prospects.
Read the full thesis - Guinness Global Equity IncomeMarch 2026
Johnson & Johnson is a diversified healthcare leader with strong pharma and medtech portfolios, resilient growth drivers, and a wide moat supporting long-term compounding.
Read the full thesis - Baron Health Care FundMarch 2026
Johnson & Johnson is a diversified health care leader with accelerating growth, strong cash flow, and a higher-multiple case.
Read the full thesis
Read every full thesis on Johnson & Johnson
Read all 3 theses in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→